654 related articles for article (PubMed ID: 31262783)
21. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
[TBL] [Abstract][Full Text] [Related]
22. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
23. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.
Sauter CS; Matasar MJ; Meikle J; Schoder H; Ulaner GA; Migliacci JC; Hilden P; Devlin SM; Zelenetz AD; Moskowitz CH
Blood; 2015 Apr; 125(16):2579-81. PubMed ID: 25758829
[TBL] [Abstract][Full Text] [Related]
26. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
27. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
Chen HH; Kuo CY; Ho CL; Chen YC
Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
[TBL] [Abstract][Full Text] [Related]
28. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.
Wu J; Meng F; Cao Y; Zhang Y; Zhu X; Wang N; Wang J; Huang L; Zhou J; Xiao Y
Blood Cancer J; 2021 Jul; 11(7):131. PubMed ID: 34267187
[TBL] [Abstract][Full Text] [Related]
29. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
31. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
[TBL] [Abstract][Full Text] [Related]
32. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
Curran KJ; Margossian SP; Kernan NA; Silverman LB; Williams DA; Shukla N; Kobos R; Forlenza CJ; Steinherz P; Prockop S; Boulad F; Spitzer B; Cancio MI; Boelens JJ; Kung AL; Khakoo Y; Szenes V; Park JH; Sauter CS; Heller G; Wang X; Senechal B; O'Reilly RJ; Riviere I; Sadelain M; Brentjens RJ
Blood; 2019 Dec; 134(26):2361-2368. PubMed ID: 31650176
[TBL] [Abstract][Full Text] [Related]
33. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.
Xin X; Zhu X; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Li C; Cao Y; Meng F; Jiang L; Zhang Y
Cell Oncol (Dordr); 2024 Apr; ():. PubMed ID: 38564164
[TBL] [Abstract][Full Text] [Related]
35. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
[TBL] [Abstract][Full Text] [Related]
36. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
37. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Dahi PB; Tamari R; Devlin SM; Maloy M; Bhatt V; Scordo M; Goldberg J; Zelenetz AD; Hamlin PA; Matasar MJ; Maragulia J; Giralt SA; Perales MA; Moskowitz CH; Sauter CS
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2004-9. PubMed ID: 25175794
[TBL] [Abstract][Full Text] [Related]
38. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
39. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
Nagler A; Perriello VM; Falini L; Falini B
Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
[TBL] [Abstract][Full Text] [Related]
40. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
Ying Z; Yang H; Guo Y; Li W; Zou D; Zhou D; Wang Z; Zhang M; Wu J; Liu H; Zhang P; Yang S; Zhou Z; Zheng H; Song Y; Zhu J
Cancer Med; 2021 Feb; 10(3):999-1011. PubMed ID: 33382529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]